🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

It was my pleasure to present the maintenance data from UPA phase III program in moderate to severe UC a the late breaker session at #UEGWeek. Every time I see that clinical effect size I look forward to better days for our patients.

Vedolizumab vs. adalimumab for ulcerative colitis - is one superior or safer for mucosal healing? A clinical trial provides new data. gastrojournal.org/article/S0016-… Uma Mahadevan David T. Rubin, MD Rick Peek Gastroenterology Laurent Peyrin-Biroulet Lorraine

During Argentinean Congress of Gastroenterology, we presented the results of a nationwide survey on IBD subjects conducted along with Fundación Mas Vida de Crohn & Colitis Ulcerosa: high proportion of self-reported limitation in quality of life due to anxiety, fatigue or working impairment. #ibd #clinicalresearch

Our IBD unit is launching a new educational activity: "Fun with IBD papers". On a monthly basis, we will be discussing methodological aspects of recently published IBD trials. Everyone is invited! #IBD #clinicaltrials #education #crohnsdisease #ulcerativecolitis

With multiple novel MoAs just around the corner, where do novel therapies for Crohn's disease stack up against the tried & true? authors.elsevier.com/a/1dyLN8nByr1G… The Lancet Gastroenterology & Hepatology Remo Panaccione, MD, FRCPC Mathurin Fumery Vipul Jairath MBChB DPhil Rocio Sedano MD

Histologic Activity Does Not Predict Future Recurrence in Postoperative Crohn’s Disease cdmcd.co/v9xKp3

Hot off the press: the entire phase III UC #etrolizumab program, 5 manuscripts in ⁦⁦The Lancet Gastroenterology & Hepatology⁩. Happy to have contributed with ⁦@ManasiAgrawalMD⁩ on the commentary “Etrolizumab for ulcerative colitis: beyond what meets the eye” thelancet.com/journals/langa…

New - Lasa et al - Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe #ulcerativecolitis: a systematic review & network meta-analysis thelancet.com/journals/langa… #IBD #GITwitter Silvio Danese Laurent Peyrin-Biroulet Juan Lasa Pablo Olivera

NEW: network meta-analysis of advanced therapies in UC; 29 RCTs including 4 head-to-head studies • upadacinitib on top for efficacy • vedolizumab on top for safety Lots to dig into here thelancet.com/journals/langa… • need more head to heads • multi-drug era for IBD is here

We will never live in a COVID-19 free world again. Accept it theglobeandmail.com/opinion/articl…

Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. Proud to have lead this study from #EIILaPrincesa with Javier P. Gisbert with the entire collaboration of the whole #ENEIDAteam of GETECCU academic.oup.com/ecco-jcc/artic…

So many amazing female role models in one room! Learned so much from colleagues and friends. The women’s leadership conference should be a DON’T MISS event @IBDConference 2022! Make your plans for next years pre-conference workshop now! Maria T. Abreu #MarlaDubinsky

Our paper, Early real-world experience with tofacitinib in ulcerative colitis - a systematic review and meta-analysis of observational studies, has just been published in Therapeutic Advances in Gastroenterology Here’s a lay summary of our work: journals.sagepub.com/doi/full/10.11… (1/)

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis | NEJM nejm.org/doi/full/10.10…

Desde la unidad de EII del CEMIC, decidimos comenzar con esta actividad dirigida para profesionales de salud. Haremos un análisis crítico sobre la metodología de estudios en EII. Para más detalle, escribir a [email protected]. Los esperamos!

Excited by the release of our new systematic review and meta-analysis on opportunistic infections in patients with inflammatory bowel diseases! Thanks to my colleagues for the great work! Pablo Olivera⁩ ⁦Ignacio Zubiaurre⁩ ⁦Laurent Peyrin-Biroulet⁩ pubmed.ncbi.nlm.nih.gov/36087107/

A must read!!! 👇🏻👇🏻👇🏻

Juan Lasa in Congreso Gastroendo. REMAR, Advanced therapy in IBD. RW study including data from 13 centers of Argentina. 👏🏻👏🏻

Results of REMAR study - a cohort study to assess advanced therapy persistence and time to dose optimisation in IBD patients from Argentina involving 14 centers - will be presented in ECCO 2023. Opening thread to show main findings

Great effort made by great group of people! Federico Cassella maria eugenia linares Deborah Balfour Claudia Fuxman Ignacio Zubiaurre Pablo Olivera Abel Novillo Domingo Balderramo Martin Toro Maricel